Tom Keith-Roach, president of AZ's UK business, said: "The UK approval of Trixeo Aerosphere with the [new] propellant marks a ...

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

AstraZeneca (AZN) said on Friday that it received positive results from two late-stage trials for its triple-combination ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat ...

May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma ...

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri ...

AstraZeneca announced on Friday that its inhaled triple-combination therapy ‘Breztri Aerosphere’ met all primary endpoints in ...